AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for promoting ~~would~~ wound healing in a subject in need of such treatment comprising administering to the subject a wound-healing effective amount of a composition containing a ~~wound-healing~~ wound-healing polypeptide selected from the group consisting of a first polypeptide comprising the amino acid sequence LKKTET (SEQ ID NO: 1) and having wound-healing activity and a second polypeptide comprising a conservative ~~variants thereof~~ variant of said amino acid sequence and having ~~wound-healing~~ wound-healing activity.

2. (Currently Amended) The method of claim 1, wherein the ~~wound-healing~~ wound-healing polypeptide is thymosin β4 or an ~~isoforms~~ isoform of thymosin β4.

3. (Original) The method of claim 2, wherein the composition further contains an agent that stimulates the production of thymosin β4 peptide.

4. (Original) The method of claim 3, wherein the agent is transforming growth factor beta (TGF-b).

5. (Currently Amended) The method of claim 1, wherein the ~~wound-healing~~ wound-healing polypeptide is delivered systemically.

6. (Currently Amended) The method of claim 1, wherein the ~~wound-healing~~ wound-healing polypeptide is delivered topically.

7. (Currently Amended) The method of claim 6, wherein the ~~wound-healing~~ wound-healing polypeptide is contained in a topical formulation selected from the group consisting of a gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel and ointment.

8. (Currently Amended) The method of claim 1, wherein the ~~wound-healing~~ wound-healing polypeptide is recombinant or synthetic.

9. (Currently Amended/Withdrawn) The method of claim 2, wherein the isoform of thymosin β4 is at least 70% homologous to thymosin β4 peptide set forth as ~~SEQ ID NO: 1 in Figure 10~~ SEQ ID NO:2.

10. (Withdrawn) The method of claim 9, wherein the isoform of thymosin β4 is selected from the group consisting of: $T\beta4^{ala}$, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14 and Tβ15.

11. (Original) The method of claim 1, further comprising contacting the site of the wound with an agent which promotes wound healing.

12. (Withdrawn) The method of claim 11, wherein the agent is selected from the group consisting of IGF, IGF-1, IGF-2, IL-I, PDGF, FGF, KGF, VEGF, prothymosin α, thymosin α I or combinations thereof.

13. (Original) A method for promoting wound healing in a subject in need of such treatment comprising administering to the subject a wound-healing effective amount of a composition containing thymosin β4 or an isoform of thymosin β4.

14. (Original) The method of claim 13, wherein the composition further contains an agent that stimulates the production of thymosin β4 peptide.

15. (Original) The method of claim 14, wherein the agent is transforming growth factor beta (TGF-b).

16. (Original) The method of claim 13, wherein the thymosin β4 is delivered systemically.

17. (Original) The method of claim 13, wherein the thymosin β4 is delivered topically.

18. (Original) The method of claim 17, wherein the thymosin β4 is contained in a topical formulation selected from the group consisting of a gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel and ointment.

19. (Original) The method of claim 13, wherein the thymosin β4 is recombinant or synthetic.

20. (Currently Amended/Withdrawn) The method of claim 13, wherein the isoform of thymosin β4 is at least 70% homologous to thymosin β4 peptide set forth as ~~SEQ HD NO:1 in Figure 10~~ SEQ ID NO:2.

21. (Withdrawn) The method of claim 13, wherein the isoform of thymosin β4 is selected from the group consisting of: $T\beta4^{ala}$, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14 and Tβ15.

22. (Original) The method of claim 13, further comprising contacting the site of the wound with an agent which promotes wound healing.

23. (Currently Amended) A method for promoting wound healing in a tissue comprising contacting the tissue with a therapeutically effective amount of a composition containing a ~~wound~~

~~healing~~ wound-healing polypeptide selected from the group consisting of a first polypeptide comprising the amino acid sequence LKKTET (SEQ ID NO: 1) and having wound-healing activity and a second polypeptide comprising a conservative ~~variants thereof~~ variant of said amino acid sequence and having ~~wound healing~~ wound-healing activity

24. (Currently Amended) The method of claim 23, wherein the ~~wound healing~~ wound-healing polypeptide is thymosin β4 or an isoform of thymosin β4.

25. (Original) The method of claim 23, wherein the contacting is *in vivo* in a subject.

26. (Original) The method of claim 23, wherein the contacting is *ex vivo*.

27. (Original) The method of claim 23, wherein the subject is a mammal.

28. (Original) The method of claim 27, wherein the mammal is human.

29. (Original) The method of claim 24, wherein the composition further contains an agent that stimulates the production of thymosin β4 peptide.

30. (Original) The method of claim 29, wherein the agent is transforming growth factor beta (TGF-b).

31. (Original) The method of claim 29, wherein the agent is a mineral.

32. (Original) The method of claim 29, wherein the mineral is zinc.

33. (Currently Amended) The method of claim 23, wherein the ~~wound healing~~ wound-healing polypeptide is delivered topically.

34. (Currently Amended) The method of claim 23, wherein the ~~wound healing~~ wound-healing polypeptide is contained in a topical formulation selected from the group consisting of a gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel and ointment.

35. (Currently Amended) The method of claim 23, wherein the ~~wound healing~~ wound-healing polypeptide is delivered systemically.

36. (Original) The method of claim 23, further comprising contacting the site of the tissue with an agent which promotes wound healing.

37. (Withdrawn) The method of claim 36, wherein the agent is selected from the group consisting of IGF, IGF-l, IGF-2, PDGF, FGF, KGF, VEGF, prothymosin α, thymosin α1 or combinations thereof.

38. (Original) The method of claim 23, wherein the tissue is selected from the group consisting of epidermal, eye, uro-genital, gastro-intestinal, cardiovascular, muscle, connective, and neural.

39. (Original) The method of claim 23, wherein the issue is skin tissue.

40. (Currently Amended) The method of claim 23, wherein the tissue is an eye tissue.

41-52. (Canceled)

53. (Original) A method of promoting epithelial cell migration, comprising contacting an epithelial cell with a composition comprising thymosin β4 or an isoform of thymosin β4 .

54. (Original) The method of claim 53, wherein the epitlelial cell is a skin cell.

55. (Original) The method of claim 54, wherein the skin cell is a keratinocyte.

56. (Original) The method of claim 53, wherein the epithelial cell is a corneal epithelial cell.

57. (Original) The method of claim 53, wherein the contacting is *in vivo*.

58. (Original) The method of claim 57, wherein the contacting is topical.

59. (Original) The method of claim 57, wherein the contacting is systemic.

60. (Original) The method of claim 53, wherein the contacting is *in vitro* or *ex vivo*.

61. (Original) The method of claim 53, wherein the composition is selected from the group consisting of a gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel, ointment, and a biocompatible matrix.

62-132. (Canceled)

133. (Previously Presented) The method of claim 1, wherein the wound is in a tissue selected from the group consisting of a skin tissue, a dermal tissue, an epidermal tissue, an eye tissue, a cornea, a retina, a uro-genital tissue, a gastro-intestinal tissue, a cardiovascular tissue, a

muscle tissue, a connective tissue, a neural tissue, a bone tissue, a cartilage tissue, a breast tissue, a central nervous system tissue, a pancreatic tissue, a liver tissue, a reticulo-endothelial system (RES) tissue and an endometrial tissue.

134. (Previously Presented) The method of claim 1, wherein the wound is present in a disease or condition selected from the group consisting of an arthritis, an osteoporosis, a musculo-skeletal disorder, a bum, an ulcer or an ulceration, a pressure ulcer, a diabetic ulcer, a skin lesion or disease, a neurological disease, a neurodegenerative disease, a nerve disease, a bone disease, a heart disease, an eye disease, corneal damage, retinal damage, skin damage, a cardiovascular disease, an ischemia, an atherosclerosis, a fibrotic disorder, a sclerotic disorder, a cancer and a cell proliferative disorder.

135. (Previously Presented) The method of claim 1, wherein the composition is administered by a route selected from the group consisting of an injection, a surgery, a catheter, a topical administration, a local injection, an inhalation, a systemic administration, an oral administration, an intranasal administration, an aerosol administration, an intravenous administration, an intraperitoneal administration, an intramuscular administration, an intracavity administration and a transdermal administration.

136. (Previously Presented) The method of claim 1, wherein the composition comprises a formulation comprising an excipient or a composition selected from the group consisting of saline, sterile water, a sodium chloride solution, lactated Ringer's intravenous, Ringer's dextrose,dextrose and sodium chloride, lactated Ringer's intravenous polyalkylene glycol, polyethylene glycol, vegetable oil, hydrogenated naphtalene, lactide polymer, lactide/glycolide copolymer, polyoxethylene-polyoxypropylene, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, phosphatidyl, phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, gangliosides; phosphatidylcholine,

dipalmitoylphosphatidylcholine, distearoylphosphatidyl-choline, injectable organic ester, ethyloleate, an alcoholic/aqueous solution, an alcoholic/aqueous emulsion, an alcoholic/aqueous suspension.

137-172. (Canceled)